RISPERDAL M-TAB |
PERSERIS KIT |
LY03004 |
R-64766 |
R-64-766 |
RCN-3028 |
RISPERIDONE |
RISPERDAL CONSTA LONG ACTING |
LY-03004 |
RISPERDAL CONSTA |
R-64,766 |
N05AX08 |
RISPERDAL |
RISPERDAL M |
RCN3028 |
RISPERDAL QUICKLET |
RISPERIDONUM |
RISPERDAL® |
RISPERIDONA |
SEQUINAN |
RISPOLEPT |
RISPERIN |
RISPOLIN |
RISPERDONE |
rxcui:35636 |
chembl:CHEMBL85 |
pubchem.compound:5073 |
chemidplus:106266-06-2 |
drugbank:00734 |
Drug Categories | antipsychotic agents (second generation [atypical]) |
FDA Approval | 1993 |
Drug Class | small molecule |
Drug Indications | Antipsychotic Agents |
Drug Class | antipsychotic agents |
Year of Approval | 1993 |
Drug Categories | adrenergic alpha-1 receptor antagonists |
Drug Categories | adrenergic alpha-antagonists |
Drug Categories | adrenergic antagonists |
Drug Categories | agents that produce hypertension |
Drug Categories | agents that reduce seizure threshold |
Drug Categories | antidepressive agents |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a5 substrates |
Drug Categories | cytochrome p-450 cyp3a7 substrates |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | dopamine d2 receptor antagonists |
Drug Categories | histamine antagonists |
Drug Categories | histamine h1 antagonists |
Drug Categories | neurotoxic agents |
Drug Categories | p-glycoprotein substrates |
Drug Categories | potential qtc-prolonging agents |
Drug Categories | qtc prolonging agents |
Drug Categories | serotonergic drugs shown to increase risk of serotonin syndrome |
Drug Categories | serotonin 5-ht1 receptor antagonists |
Drug Categories | serotonin 5-ht2 receptor antagonists |
Drug Categories | serotonin receptor antagonists |
antagonist (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Inverse agonist |
Endogenous Drug? | False |
Mechanism of Interaction | Serotonin 2c (5-HT2c) receptor antagonist |
antagonist (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
Specific Action of the Ligand | Inverse agonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Inverse agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Direct Interaction? | True |
Endogenous Drug? | False |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
Direct Interaction? | True |
RISPERIDONE | DrugBank Drug Name |
106266-06-2 | CAS Number |
Act Risperidone | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
RISPERIDONE | Primary Drug Name |
Year of Approval | 1993 |
Drug Class | antipsychotic agents |
Drug Indications | Antipsychotic Agents |
Drug Class | small molecule |
FDA Approval | 1993 |
C29416 | NCI drug code |
CHEMBL85 | ChEMBL Drug ID |
RISPERIDONE | GuideToPharmacology Ligand Name |
D01AZG | TTD Drug ID |